Cargando…
Case Report: Vemurafenib Treatment in Brain Metastases of BRAF(S365L)-Mutant Lung Papillary Cancer by Genetic Sequencing of Cerebrospinal Fluid Circulating Tumor DNA Detection
BRAF mutations, primarily sensitizing mutations, such as BRAF(V600E), have been proven to response to the BRAF inhibitor, Dabrafenib combined with trametinib therapy, but there have been no data demonstrating that it has activity against NSCLC-related brain metastases (BM). How patients harboring BR...
Autores principales: | Jiang, Jianing, Gao, Jinqi, Wang, Gang, Lv, Jinyan, Chen, Wenting, Ben, Jing, Wang, Ruoyu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8226071/ https://www.ncbi.nlm.nih.gov/pubmed/34178685 http://dx.doi.org/10.3389/fonc.2021.688200 |
Ejemplares similares
-
Pronounced response of papillary craniopharyngioma to treatment with vemurafenib, a BRAF inhibitor
por: Aylwin, Simon J. B., et al.
Publicado: (2015) -
Aggressive Childhood-onset Papillary Craniopharyngioma Managed With Vemurafenib, a BRAF Inhibitor
por: Chik, Constance L, et al.
Publicado: (2021) -
VCAM-1 Upregulation Contributes to Insensitivity of Vemurafenib in BRAF-Mutant Thyroid Cancer
por: Chen, Shitu, et al.
Publicado: (2020) -
Silencing FOXP2 reverses vemurafenib resistance in BRAF(V600E) mutant papillary thyroid cancer and melanoma cells
por: Jiang, Suyuan, et al.
Publicado: (2022) -
Extended Antitumor Response of a BRAF V600E Papillary Thyroid Carcinoma to Vemurafenib
por: Ali, Siraj M., et al.
Publicado: (2014)